Strides Pharma Science

What Strides Pharma Science does

Strides Pharma Science Limited, founded in 1990 and headquartered in Bengaluru, is a publicly listed Indian pharmaceutical company (NSE: STAR) that develops, manufactures, and commercializes IP-led niche generic formulations across oral solids, modified-release dosages, topicals, nasal sprays, hormones, and controlled substances. The company operates seven state-of-the-art manufacturing facilities across India, the United States, Italy, and Kenya, with combined annual capacity exceeding 16 billion dosage units, and holds approvals from USFDA, MHRA, TGA, WHO, ANVISA, and other major regulators. It commercializes over 1,000 formulations reaching more than 100 countries.

The company operates four integrated business lines: (1) a regulated-markets generics franchise (US, Canada, Australia, New Zealand, UK, Nordics, DACH) anchored by Strides Pharma Inc. and Strides Pharma International AG; (2) a donor-funded institutional business supplying WHO-prequalified and PEPFAR-approved formulations for HIV/AIDS, malaria, tuberculosis, and hepatitis to Global Fund, USAID, UNICEF, PAHO, UNITAID, and PEPFAR; (3) the Brands Africa branded-generics platform covering 40+ African countries; and (4) specialty/differentiated generics and co-development partnerships (e.g., with Kenox Pharmaceuticals on nasal sprays). UCL Kenya functions as an extended WHO-prequalified manufacturing arm for African and donor-funded programs.

In FY26, Strides reported consolidated revenue of approximately Rs 4,858.68 crore (~$580 million), up 6.43% year-over-year, with a three-year CAGR of approximately 12%. EBITDA margins expanded 400 basis points to 19%, and net debt-to-EBITDA improved from 1.9x to 1.55x. The company has been actively reshaping its portfolio through the demerger and separate listing of OneSource Specialty Pharma (CDMO, January 2025), the sale of an 80.05% stake in Pivot Path to Ascent Capital for Rs 100 crore (June 2026), and the $12 million acquisition of Sandoz's branded generics portfolio for Sub-Saharan Africa (March 2026). Over 60 pending low-competition US launches target $400 million in revenue by FY28.

Name

Strides Pharma Science

Legal name

Strides Pharma Science Limited

Website

https://strides.com

Company type

Public

Founded year

1990

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Strides Pharma Science is a publicly listed Indian pharmaceutical company that develops, manufactures, and commercializes IP-led generic formulations across 100+ countries, serving regulated markets, donor-funded public health programs, and African branded generics through seven global manufacturing facilities.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

akta.pro secondary industries

Generic Hospital & Institutional Products (HLAIABAL), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Generic pharmaceuticals
• Complex generics manufacturing
• Institutional public health
• Branded generics Africa
• Active pharmaceutical ingredients

Headquarters

HQ city

Bangalore

HQ country

India

HQ region

Asia

Offices16 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Commercial Generic Pharmaceuticals: Sale of generic pharmaceutical products across regulated markets (US, Europe, Australia) and emerging markets (Africa, Asia Pacific, LATAM, MENA). Revenue generated through ANDAs, product launches, and market penetration. US market faces headwinds from weaker flu season and competition, while Ex-US markets contribute nearly 50% of revenue.
2. Institutional/Public Health Business: Supply of essential medicines to donor-funded programs and international procurement agencies including Global Fund, USAID, UNICEF, PAHO, UNDP, PEPFAR. Products include WHO-prequalified formulations for HIV/AIDS, malaria, tuberculosis, and hepatitis treatments.
3. Branded Generics (Africa): Sale of branded generic products in Africa through Brands Africa initiative. Products include Renerve, Combiart, Duotab, Vitafer, Unibrol for neuropathy, anaemia, malaria treatment. Operating in over 40 African countries with commercial field force.
4. Contract Manufacturing (OneSource): OneSource Specialty Pharma (demerged and listed separately in January 2025) provides contract manufacturing services for GLP-1 and complex therapeutics. Projecting revenue growth from $170 million FY25 to $500 million by FY28 with 40% EBITDA margins.

Go-to-market motion3 records

Distribution channels7 records

Marketing channels7 records

Core offering

Strides Pharma Science develops, manufactures, and commercializes IP-led niche generic pharmaceuticals across diverse dosage forms including oral solids, modified-release formulations, topicals, nasal sprays, hormones, and controlled substances. The company operates through four integrated business models: (1) regulated-market generics in the US, Europe, Canada, Australia, and New Zealand; (2) institutional public health medicines for HIV/AIDS, malaria, tuberculosis, and hepatitis through donor-funded programs; (3) branded generics in 40+ African countries under the Brands Africa initiative; and (4) WHO-prequalified contract manufacturing through its Kenya-based Universal Corporation Limited (UCL) facility.

Product overview

Strides Pharma Science is a global pharmaceutical company specializing in the development and manufacturing of IP-led niche generics across diverse dosage forms including tablets, capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. The company operates through multiple integrated business models: (1) a US-focused generics business with ANDAs and OTC products; (2) an institutional/public health medicines division supplying donor-funded programs for HIV/AIDS, malaria, and TB; (3) branded generics businesses in Africa (Brands Africa) and regulated markets (UK, DACH, Nordics); and (4) WHO-prequalified manufacturing through its Kenya-based Universal Corporation Limited facility. The portfolio spans anti-infectives, CNS, cardiovascular, gastroenterology, pain management, and specialty formulations.

Differentiator

Problem solved

Functional benefit

Brands

• Renerve: Brand for neuropathy treatment in Africa
• Combiart
• Duotab
• Vitafer
• Unibrol

Products and services

• Generic Pharmaceuticals Portfolio
• Institutional/Public Health Medicines
• Brands Africa - Branded Generics
• US Market Generic Pharmaceuticals
• Strides UK - Generic and OTC Medicines
• Strides Pharma International AG - DACH Region Portfolio
• Canada Generic Pharmaceuticals
• Universal Corporation Limited (UCL) - WHO-Prequalified Manufacturing
• Trinity Pharma Partnership - Southern Africa
• Nasal Spray Product Portfolio (OINDP)

Quantifiable outcome

• Ex-US markets contributed nearly 50% of Q4 FY26 revenue, demonstrating successful diversification strategy
• +4 more outcomes

Named customers11 records

Segments6 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

14 partnerships are on record, tiered core.

• Sandoz AGcoreStrategic or Co-development Partner · 17 March 2026Strides Pharma acquired Sandoz's portfolio of branded generic products for Sub-Saharan Africa for $12 million (approximately ₹111 crore). Portfolio includes anti-infective, cardiovascular, and dermatology products targeting Western Sahara, Ghana, Nigeria, and Kenya markets.
• Kenox Pharmaceuticals Inc.coreStrategic or Co-development Partner · 9 September 2025Strategic product development partnership to develop multiple nasal spray products for the US market across diverse therapeutic indications. Kenox provides formulation and development expertise in Orally Inhaled and Nasal Drug Products (OINDPs), combining with Strides' manufacturing and commercial strengths.
• Universal Corporation Limited (UCL)coreStrategic or Co-development PartnerWHO-prequalified pharmaceutical manufacturer in Kenya serving as extended manufacturing arm for Strides under donor-funded contracts. Produces critical formulations including TLD (Tenofovir/Lamivudine/Dolutegravir) and Artemether/Lumefantrine for HIV/AIDS and malaria programs. Serves 30+ countries across Africa, Middle East, and donor markets.
• Trinity PharmacoreChannel Partner/ Reseller/ DistributorSouth Africa-based pharmaceutical partnership to serve private and public healthcare sectors in South Africa, Namibia, Botswana, and Lesotho. Broad therapeutic footprint spanning all major categories except oncology with deep regulatory expertise.
• Global FundcoreChannel Partner/ Reseller/ DistributorApproved supplier of WHO-prequalified formulations for HIV/AIDS, malaria, and tuberculosis through donor-funded programs serving disease-affected regions globally.
• USAIDcoreChannel Partner/ Reseller/ DistributorSupply of essential medicines to disease-affected regions through US government international development aid programs.
• UNICEFcoreChannel Partner/ Reseller/ DistributorEssential medicines supply for global child health programs and disease interventions through UNICEF procurement channels.
• Clinton Health Access InitiativecoreStrategic or Co-development PartnerStrategic collaboration expanding access to essential medicines and treatments in low and middle-income countries through program support and market-shaping initiatives.
• Medicines Patent PoolcoreStrategic or Co-development PartnerCollaboration through licensing and voluntary pool mechanisms to expand access to patented medicines in developing countries.
• Medicines for Malaria VenturecoreStrategic or Co-development PartnerProduct development partnerships for malaria treatments, contributing to global malaria control efforts through affordable, quality-assured medicines.
• ViiV HealthcarecoreStrategic or Co-development PartnerLicensing partnerships for HIV/AIDS treatments including dolutegravir-based formulations. Supported by technology transfer and manufacturing capabilities.
• Gilead SciencescoreStrategic or Co-development PartnerAntiviral treatments collaboration through licensing, technology transfer, and supply arrangements for hepatitis and HIV treatments.
• PAHOcoreChannel Partner/ Reseller/ DistributorEssential medicines supply across Latin American and Caribbean regions through PAHO's regional procurement mechanisms.
• UNITAIDcoreChannel Partner/ Reseller/ DistributorHIV/AIDS, hepatitis, and tuberculosis treatments supply through international procurement agency for underserved markets.

Scale indicators17 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• Lupin: Indian generic pharma with US ANDA focus and complex generics capabilities. Direct peer across regulated-market strategy, manufacturing footprint, and emerging-markets push.
• Zydus Lifesciences: Indian pharmaceutical company with US generics, biosimilars, and a wide emerging-markets presence. Comparable in scale, geographic mix, and pipeline depth.
• Glenmark Pharmaceuticals: Indian pharma with branded generics, complex generics, and specialty/API exposure. Overlaps with Strides in niche generics strategy and emerging-markets commercial model.
• Cipla: Indian pharma major with strong presence in HIV/AIDS, respiratory, and institutional/global health segments. Highly comparable in the donor-funded institutional franchise and Africa footprint.
• Aurobindo Pharma: Indian generic major with a similarly large US ANDA portfolio, multiple manufacturing facilities, and significant emerging-markets exposure. Closely comparable business model spanning regulated and emerging markets.
• Dr. Reddy's Laboratories: Indian generic pharmaceutical company with parallel US ANDA pipeline, complex generics focus, and emerging-markets operations. Direct competitor across oral solids, injectables, and biosimilars.
• Alembic Pharmaceuticals: Indian generic pharma with US ANDA focus, India branded business, and international operations. Comparable in size, pipeline orientation, and emerging-market ambitions.

Broad incumbents

• Sun Pharmaceutical Industries: Largest Indian pharma company with a much broader specialty and generics portfolio including branded US. Larger and more diversified, but the closest reference point for Strides' market positioning.
• Viatris: Global generics and biosimilars major with deep institutional/global-health channel and a broad off-patent portfolio. Reference peer for the international institutional and Africa segments where Strides competes.

Emerging players

• Natco Pharma: Indian pharma focused on complex generics and oncology with strong US niche-ANDA strategy. Comparable in IP-led differentiation and focus on limited-competition launches.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/strides_pharma
• Facebookfacebook.com/stridespharmascience
• LinkedInin.linkedin.com/company/strides-pharma

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries14 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Strides Pharma Science